SPL028

SPL028, or SPL-028, also known as α,α-dideutero-N,N-dimethyltryptamine (D₂-DMT), is a psychedelic drug of the tryptamine family which is under development for the treatment of depressive disorders.^[2][3][4][5] It is the analogue of dimethyltryptamine (DMT) in which the α carbon has been dideuterated.^[2][6] SPL028's route of administration is intravenous injection or intramuscular injection.^[1]

SPL028

Clinical data
Other names	SPL-028; α,α-Dideutero-N,N-dimethyltryptamine; N,N-D2-dimethyltryptamine; D2-DMT
Routes of administration	Intravenous injection, intramuscular injection[1]
Drug class	Serotonin receptor modulator; Serotonergic psychedelic; Hallucinogen
ATC code	None
Identifiers
PubChem CID	10241628
ChemSpider	8417115
Chemical and physical data
3D model (JSmol)	Interactive image
SMILES [2H]C([2H])(CC1=CNC2=CC=CC=C21)N(C)C
InChI InChI=1S/C12H16N2/c1-14(2)8-7-10-9-13-12-6-4-3-5-11(10)12/h3-6,9,13H,7-8H2,1-2H3/i8D2 Key:DMULVCHRPCFFGV-MGVXTIMCSA-N

The drug shows similar pharmacodynamics as DMT in vitro.^[2][6] Relatedly, SPL028 generalized with DMT in rodent drug discrimination tests.^[6][7] On the other hand, SPL028 differs from DMT in terms of pharmacokinetics; it is more resistant to metabolism and shows a prolonged duration.^[2][6][7] In a phase 1 clinical trial, SPL-028 by intramuscular injection produced robust psychedelic effects of short duration in humans.^[8]

SPL028 was originated by Small Pharma and is under development by Cybin.^[4] Small Pharma was acquired by Cybin in 2023.^[9] As of February 2024, SPL028 is in phase 1 clinical trials.^[4]

See also

• List of investigational hallucinogens and entactogens
• CYB004 (deuterated dimethyltryptamine; dDMT)